Skip Navigation

Alvotech appoints new Chief Scientific Officer

30 September 2019

Alvotech has appointed Joseph Edward McClellan as its new Chief Scientific Officer. McClellan will be leading the company’s R&D functions, with overall responsibility for bringing products to market through its pipeline and overseeing R&D operations across Alvotech’s sites in Reykjavik, Julich, Hanover and Zurich.

McClellan joins Alvotech with an outstanding track record in drug development with broad experience in all areas of biopharmaceutical development, including biosimilars, innovator biologics, pharmaceutical science, clinical development, regulatory strategy and discovery research.

Prior to joining Alvotech, McClellan worked with Pfizer for 17 years in various capacities, including Global Head of Biosimilars Development and Medicine/Asset Team Leader of IXIFI (biosimilar infliximab).

McClellan is seen as a great asset to Alvotech’s team since he is an insightful scientist and a proven leader with a track record in driving forward end-to-end biopharmaceutical development programs, whilst ensuring strategic, scientific and operational excellence.